Breakthrough-Style Program For ANDAs Added To House User Fee Bill
Executive Summary
Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.
You may also be interested in...
Competitive Generic Therapies Get Help With Development, But Not Goal Date
Draft guidance says US FDA will try to expedite assessment of competitive generic therapy designees, but will not give shorter review goals.
US FDA’s First Competitive Generic Therapy Approval Comes With A Twist
Apotex’s potassium chloride oral solution is eligible for 180-day exclusivity under new expedited pathway even though Amneal’s generic referencing same product was approved three weeks earlier; Amneal's continued marketing will not be blocked by Apotex’s exclusivity, which is forfeited if it fails to launch within 75 days.
US FDA’s First Competitive Generic Therapy Approval Comes With A Twist
Apotex’s potassium chloride oral solution is eligible for 180-day exclusivity under new expedited pathway even though Amneal’s generic referencing same product was approved three weeks earlier; Amneal's continued marketing will not be blocked by Apotex’s exclusivity, which is forfeited if it fails to launch within 75 days.